Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP) — StellaEarly Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations(2 sites)
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Age range
18 Years and older
Last updated November 2025